Latest Antibody Stories
BREDA, The Netherlands, May 28, 2014 /PRNewswire/ -- arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies
Protection Data Presented at the 17th Annual Meeting of the American Society of Gene & Cell Therapy BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
ReportsnReports.com offers "Antibody Drug Conjugate Market Opportunity Analysis" report to its research database.
CAMBRIDGE, England, May 16, 2014 /PRNewswire/ -- Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation Kymab, a monoclonal
Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc.
Our bodies produce a family of proteins that recognize and kill bacteria whose carbohydrate coatings resemble those of our own cells too closely.
Tumors shrank or disappeared in some patients with advanced neuroblastoma in a Phase I study of an immune therapy manufactured at St.
OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug
Two separate studies this week are helping scientists gain a better understanding of the dangerous Middle East respiratory syndrome (MERS) coronavirus, a disease that has sickened more than 300 people and left at least a hundred dead since it was first reported in September 2012.
Extension of trade name reflects growth in customized primary cell biology contract research business SEATTLE, April 28, 2014 /PRNewswire/ -- ReachBio LLC announced today that it is
- A poem in which the author retracts something said in an earlier poem.
More Images (4 images) »